Bonesupport taps pharma veteran for CEO
This article was originally published in Clinica
Bonesupport, a Swedish specialist in injectable bone substitutes and drug-eluting bone scaffolds, has appointed Richard Davies as CEO. Davies’ experience has mainly been with pharma companies, including Eli Lilly and Amgen, where he held various senior roles managing different geographic markets. Prior to joining Lund-based Bonesupport, he served as chief commercial offer at Hospira, before it was acquired by Pfizer last year. Davies replaces Lloyd Diamond, who will transition to the role of chief business officer. The latter will re-locate back to the US and help drive commercial growth of Bonesupport’s lead product, Cerament, in that market. In his four years as Bonesupport’s CEO, Diamond took the company past the R&D phase and into commercialization. The new CEO expects his pharmaceutical experience will help leverage the drug-eluting capabilities of Cerament.
Register for our free email digests: